Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRuE-HS2 study of ruxolitinib cream in hidradenitis suppurativa
NL-OMON59172Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ruxolitinib in hidradenitis suppurativa (HS) (3 arms), sponsored by Incyte. Primary endpoint: HiSCR75 at Week 16. Started Dec 2025; status: active, not recruiting.
02
Drugs
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON59172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59172.